Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
NOT YET RECRUITING
NCT07486960
PHASE2
Study to Evaluate Tulisokibart in Adults With Psoriatic Arthritis (MK-7240-015)
Sponsor: Merck Sharp & Dohme LLC
View on ClinicalTrials.gov
Summary
This study assesses the efficacy, safety, and tolerability of tulisokibart (MK-7240) in adult participants with active Psoriatic Arthritis.
Official title: A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tulisokibart in Participants With Psoriatic Arthritis.
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
140
Start Date
2026-04-22
Completion Date
2030-01-11
Last Updated
2026-03-23
Healthy Volunteers
No
Conditions
Interventions
DRUG
Tulisokibart
Subcutaneous administration
DRUG
Placebo
Subcutaneous administration